Product Information
TRIAZOLAM 0.125 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.2628 per EA under NDC 59762371709. Its NADAC has been published 498 times since Mar 22, 2017.
FDA first approved this application on Nov 15, 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.125 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762371709
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TRIAZOLAMApproval Type
Authorized Generic (NDA)
FDA Application
NDA017892FDA Approved
11/15/1982
TE Code
AB
On Market Since
11/15/1982
Pharmacological Classes
Price Statistics
The NADAC for TRIAZOLAM 0.125 MG TABLET has been published 498 times since Mar 22, 2017, and over the history we have for it it has declined 79.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2628 per EA |
|---|---|
| All-time high | $1.7887 (May 13, 2020) |
| All-time low | $0.2219 (Jan 22, 2025) |
| 52-week high | $0.3975 |
| 52-week low | $0.2628 |
| Median price | $1.0889 |
| Average price | $1.0144 |
| Largest weekly change | +49.3% (Mar 23, 2022) |
| Weeks tracked | 498 |
| Tracking since | Mar 22, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the triazolam market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
triazolam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRIAZOLAM 0.125 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRIAZOLAM 0.125 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.2628 per EA (NDC 59762371709), effective Sep 30, 2026.
How has the price of TRIAZOLAM 0.125 MG TABLET changed over time?
Over the history we have for it, the NADAC for TRIAZOLAM 0.125 MG TABLET has declined 79.9%. It has been tracked across 498 weekly CMS publications since Mar 22, 2017.
What are the highest and lowest recorded NADAC prices for TRIAZOLAM 0.125 MG TABLET?
Since Mar 22, 2017, the NADAC for TRIAZOLAM 0.125 MG TABLET has ranged from a low of $0.2219 (Jan 22, 2025) to a high of $1.7887 (May 13, 2020), with a median of $1.0889 per EA.
Are there cheaper alternatives to TRIAZOLAM 0.125 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of TRIAZOLAM 0.125 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TRIAZOLAM 0.125 MG TABLET?
TRIAZOLAM 0.125 MG TABLET (NDC 59762371709) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.